Join to View Full Profile
101 Nicolls RdBoston, MA 11794
Phone+1 617-726-2797
Fax+1 617-726-6131
Dr. Cutie is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Harvard Medical SchoolResidency, Urology, 2005 - 2008- Mass General Brigham/Massachusetts General HospitalResidency, Surgery, 2003 - 2005
Yale School of MedicineClass of 2003
Certifications & Licensure
MA State Medical License 2008 - 2023
Clinical Trials
- Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder Start of enrollment: 2017 Apr 04
- Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer Start of enrollment: 2019 Jan 02
Publications & Presentations
PubMed
- Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.Siamak Daneshmand, Ashish M Kamat, Neal D Shore, Joshua J Meeks, Matthew D Galsky
Urologic Oncology. 2025-05-01 - 9 citationsThe Safety, Tolerability, and Preliminary Efficacy of a Gemcitabine-releasing Intravesical System (TAR-200) in American Urological Association-defined Intermediate-ris...F Johannes P van Valenberg, Antoine G van der Heijden, Christopher J Cutie, Sumeet Bhanvadia, Kirk A Keegan
European Urology Open Science. 2024-04-01 - Reply by Authors.Mark D Tyson, David Morris, Juan Palou, Oscar Rodriguez, Maria Carmen Mir
The Journal of Urology. 2023-05-01
Other
- Overview of vasectomyCutie CJ, Ongaro TJ
http://www.uptodate.com/contents/overview-of-vasectomy
UpToDate, Wolters Kluwer Health - 2009-09-23
Press Mentions
New Data from J&j’s Bladder Cancer Drug-Device Trial Strengthens Support for NDAApril 28th, 2025- Johnson & Johnson’s TAR-200 Monotherapy Achieves High Disease-Free Survival of More Than 80 Percent in BCG-Unresponsive, High-Risk Papillary NMIBCApril 26th, 2025
- Johnson & Johnson's TAR-200 Monotherapy Demonstrates Highest Complete Response Rate with Sustained Clinical Benefits in Patients with Certain Types of Bladder CancerApril 26th, 2025
- Join now to see all
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
